tiprankstipranks
Advertisement
Advertisement

AU:CU6 Stock Latest News

Citigroup Ceases to Be Substantial Holder in Clarity Pharmaceuticals
Company AnnouncementsCitigroup Ceases to Be Substantial Holder in Clarity Pharmaceuticals
1d ago
CU6
Clarity Pharmaceuticals Director Colin Biggin Steps Down but Retains Significant Equity Stake
PremiumCompany Announcements
Clarity Pharmaceuticals Director Colin Biggin Steps Down but Retains Significant Equity Stake
3d ago
CU6
Clarity Pharmaceuticals Reshapes Board as It Moves Toward Commercial Launch
PremiumCompany Announcements
Clarity Pharmaceuticals Reshapes Board as It Moves Toward Commercial Launch
3d ago
CU6
Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme
PremiumCompany Announcements
Clarity Pharmaceuticals Issues New Unquoted Options Under Employee Incentive Scheme
5d ago
CU6
Clarity Pharmaceuticals Issues New Shares on Option Exercise in Routine Capital Move
PremiumCompany Announcements
Clarity Pharmaceuticals Issues New Shares on Option Exercise in Routine Capital Move
11d ago
CU6
Clarity Pharmaceuticals Seeks ASX Quotation for Small Tranche of New Shares
PremiumCompany AnnouncementsClarity Pharmaceuticals Seeks ASX Quotation for Small Tranche of New Shares
11d ago
CU6
Clarity’s PSMA Imaging Agent Shows Superior Performance in Key Prostate Cancer Study
Premium
Company Announcements
Clarity’s PSMA Imaging Agent Shows Superior Performance in Key Prostate Cancer Study
12d ago
CU6
Clarity Secures Major U.S. Copper-64 Supply Deal with Theragenics
Premium
Company Announcements
Clarity Secures Major U.S. Copper-64 Supply Deal with Theragenics
18d ago
CU6
Clarity’s 64Cu-SAR-bisPSMA tops standard imaging in prostate cancer trial
PremiumCompany Announcements
Clarity’s 64Cu-SAR-bisPSMA tops standard imaging in prostate cancer trial
26d ago
CU6
Clarity Pharmaceuticals Issues New Shares via Option Exercises, Confirms Regulatory Compliance
PremiumCompany Announcements
Clarity Pharmaceuticals Issues New Shares via Option Exercises, Confirms Regulatory Compliance
1M ago
CU6
Clarity Pharmaceuticals Seeks ASX Quotation for New Share Issuance
PremiumCompany Announcements
Clarity Pharmaceuticals Seeks ASX Quotation for New Share Issuance
1M ago
CU6
Clarity hits Phase III AMPLIFY enrollment goal for prostate cancer imaging agent
PremiumCompany Announcements
Clarity hits Phase III AMPLIFY enrollment goal for prostate cancer imaging agent
1M ago
CU6
Clarity Pharmaceuticals Issues Additional Unquoted Employee Options
PremiumCompany AnnouncementsClarity Pharmaceuticals Issues Additional Unquoted Employee Options
1M ago
CU6
Clarity Pharmaceuticals Releases 2026 Interim Report Detailing Pipeline and Financial Progress
Premium
Company Announcements
Clarity Pharmaceuticals Releases 2026 Interim Report Detailing Pipeline and Financial Progress
1M ago
CU6
Clarity Pharmaceuticals Posts Wider Half-Year Loss but Lifts Net Tangible Assets
Premium
Company Announcements
Clarity Pharmaceuticals Posts Wider Half-Year Loss but Lifts Net Tangible Assets
1M ago
CU6
Clarity flags more prostate cancer patients with no detectable disease in SECuRE trial
PremiumCompany Announcements
Clarity flags more prostate cancer patients with no detectable disease in SECuRE trial
2M ago
CU6
Clarity Advances Late-Stage Radiopharmaceutical Pipeline on Strong Cash Base
PremiumCompany Announcements
Clarity Advances Late-Stage Radiopharmaceutical Pipeline on Strong Cash Base
2M ago
CU6
Clarity’s SECuRE Prostate Cancer Trial Clears Safety Review and Advances Toward Phase III
PremiumCompany Announcements
Clarity’s SECuRE Prostate Cancer Trial Clears Safety Review and Advances Toward Phase III
3M ago
CU6
Clarity Pharmaceuticals Options Lapse, Simplifying Capital Structure
PremiumCompany Announcements
Clarity Pharmaceuticals Options Lapse, Simplifying Capital Structure
3M ago
CU6
Clarity’s Prostate Cancer Imaging Data Secures Prime Spot at Major European Urology Congress
PremiumCompany AnnouncementsClarity’s Prostate Cancer Imaging Data Secures Prime Spot at Major European Urology Congress
4M ago
CU6
Clarity Wins FDA Backing for Phase III Trial of Cu-64 SARTATE in Neuroendocrine Tumours
Premium
Company Announcements
Clarity Wins FDA Backing for Phase III Trial of Cu-64 SARTATE in Neuroendocrine Tumours
4M ago
CU6
Clarity Pharmaceuticals Showcases Superior Imaging Agent at ASCO-GI 2026
Premium
Company Announcements
Clarity Pharmaceuticals Showcases Superior Imaging Agent at ASCO-GI 2026
4M ago
CU6

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >